标题
Management of cardiovascular complications of bruton tyrosine kinase inhibitors
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-09-09
DOI
10.1111/bjh.17788
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
- (2020) Nitin Jain et al. BLOOD
- Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Jennifer A. Woyach et al. Cancer Discovery
- Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
- (2020) Yutao Guo et al. AMERICAN JOURNAL OF MEDICINE
- The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants
- (2020) Michal Ariela Raz et al. BRITISH JOURNAL OF HAEMATOLOGY
- ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2020) Peter Hillmen et al. Future Oncology
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation
- (2020) Yutao Guo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population‐based study
- (2020) Karin Larsson et al. BRITISH JOURNAL OF HAEMATOLOGY
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
- (2019) Constantine Si Lun Tam et al. BLOOD
- Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI
- (2019) Davide Capodanno et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension and incident cardiovascular events following ibrutinib initiation
- (2019) Tyler Dickerson et al. BLOOD
- Cardiovascular adverse events of ibrutinib
- (2019) Inhye E. Ahn BLOOD
- Cardiovascular Toxicities Associated With Ibrutinib
- (2019) Joe-Elie Salem et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
- (2019) John C. Byrd et al. BLOOD
- Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib
- (2018) Jari M. Tuomi et al. CANADIAN JOURNAL OF CARDIOLOGY
- Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
- (2018) Susan O'Brien et al. Clinical Lymphoma Myeloma & Leukemia
- Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
- (2018) Connie Cheng et al. LEUKEMIA & LYMPHOMA
- Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors
- (2018) Tze-Fan Chao et al. THROMBOSIS AND HAEMOSTASIS
- Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study
- (2018) Wei-Syun Hu et al. Oncotarget
- CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer
- (2018) Maria D’Souza et al. European Journal of Preventive Cardiology
- Antithrombotic Therapy for Atrial Fibrillation
- (2018) Gregory Y.H. Lip et al. CHEST
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
- (2018) Avirup Guha et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
- (2018) Jennifer R. Brown et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
- (2018) Ping G. Tepper et al. PLoS One
- Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review
- (2018) Ethan Borre et al. THROMBOSIS AND HAEMOSTASIS
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
- (2017) J. J. Shatzel et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
- (2017) Chloe Pek Sang Tang et al. LEUKEMIA & LYMPHOMA
- The ABC pathway: an integrated approach to improve AF management
- (2017) Gregory Y. H. Lip Nature Reviews Cardiology
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Causes of Death and Influencing Factors in Patients with Atrial Fibrillation
- (2016) Laurent Fauchier et al. AMERICAN JOURNAL OF MEDICINE
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
- (2016) Darryl P. Leong et al. BLOOD
- Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
- (2016) Philip A. Thompson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
- (2016) L de Zwart et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Causes of Death in Anticoagulated Patients With Atrial Fibrillation
- (2016) Antonio Gómez-Outes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores
- (2016) G. Y. H. Lip et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
- (2016) Jeff S Healey et al. LANCET
- Rate control in atrial fibrillation
- (2016) Isabelle C Van Gelder et al. LANCET
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
- (2016) Xinfang Xie et al. LANCET
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
- (2016) Heidi D. Finnes et al. LEUKEMIA & LYMPHOMA
- Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
- (2016) Tait D. Shanafelt et al. LEUKEMIA & LYMPHOMA
- Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
- (2016) Allison Keshishian et al. THROMBOSIS AND HAEMOSTASIS
- Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
- (2016) Jeroen Jaspers Focks et al. BMJ-British Medical Journal
- Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
- (2016) Jeroen Jaspers Focks et al. BMJ-British Medical Journal
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Taking the pulse of atrial fibrillation
- (2015) Brian J Potter et al. LANCET
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
- (2015) Deborah M. Siegal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Left atrial volume and function in patients with atrial fibrillation
- (2014) Darryl P. Leong et al. CURRENT OPINION IN CARDIOLOGY
- Adverse prognosis of incidentally detected ambulatory atrial fibrillation
- (2014) Carlos Martinez et al. THROMBOSIS AND HAEMOSTASIS
- Insights Into Onco-Cardiology
- (2013) Dimitrios Farmakis et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation
- (2012) Leif Friberg et al. CIRCULATION
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
- (2008) Denis Roy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started